602 Is There a Role for Allografting in Myeloma in the Era of New Drugs?: Long-Term Follow-Up of a Comparative Study

We conducted a trial where treatment depended on the presence of HLA-identical siblings. Induction included an autograft, followed by a non-myeloablative allograft or a second autograft. At a median of 7.1 years, OS and EFS were significantly longer in patients with HLA-matched siblings and in those who underwent the allograft.